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Aims We studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients
hospitalized for acute heart failure (AHF).
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Methods
and results
RELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who
were randomized to 48 h i.v infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation.
Diuretic response was defined as Δ weight kg/[(total i.v. dose)/40mg]+ [(total oral dose)/80mg)] furosemide (or
equivalent loop diuretic dose) up to day 5. Median diuretic response was −0.42 (−1.00, −0.14) kg/40mg. A poor
diuretic response was independently associated with Western-like region (Western Europe, North America, Israel,
and Poland), lower diastolic blood pressure, the absence of oedema, higher blood urea nitrogen, and lower levels
of aspartate aminotransferase and potassium (all P< 0.01). Randomization to serelaxin was associated with lower
doses of i.v. loop diuretics and slightly less weight loss, resulting in a neutral effect on diuretic response. Worse
diuretic response was independently associated both with less relief of dyspnoea, measured with a visual analogue
scale (VAS) at day 5 (primary endpoint; P= 0.0002), and with a higher risk of cardiovascular death or rehospitalization
for heart failure or renal failure through day 60 (secondary endpoint, P< 0.0001), but not with increased 180-day
cardiovascular mortality (P= 0.507).
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Conclusions In patients hospitalized for AHF, a poor diuretic response was associated with a poor in-hospital and early
post-discharge clinical outcome. Serelaxin had a neutral effect on diuretic response.
Trial registration: NCT00520806
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Introduction
Acute heart failure (AHF) is a life-threatening condition needing
immediate medical attention and often requiring urgent hospital
admission.1,2 Hospitalization for AHF is associated with a high
risk of both in-hospital and post-discharge mortality and hospital
readmission for heart failure.3–7 Several studies tried to identify
patients at risk, but they could only moderately predict mortality
and poorly predict readmission.8–11 In addition, most of the
factors predicting outcome in these models are non-modifiable,
such as age.
Treatment options in AHF are often limited to treatment with
i.v. loop diuretics. However, not every patient responds well to
their diuretic treatment, although our understanding of diuretic
resistance is limited. Therefore, there is a need to better charac-
terize and understand factors related to a poor diuretic response.
Recently, we and others showed that a poor diuretic response,
defined as weight loss per unit loop diuretic during the first 5 days
after hospital admission, was strongly associated with in-hospital
worsening heart failure, and predicted mortality and heart fail-
ure rehospitalization.12,13 In addition, rolofylline, an adenosine A1
antagonist, was shown to improve diuretic response, although the
neutral findings of PROTECT halted the development of rolofylline.
Serelaxin is a novel drug that holds promise for the treatment of
patients with AHF.14,15 However, the effects of serelaxin on diuretic
response have so far not been studied. In the present study, we
aimed to describe patient characteristics, incidence of worsening
renal function, and outcomes related to diuretic response in AHF
patients. In addition, we studied the effects of serelaxin on diuretic
response, both at the end of infusion of serelaxin at 48 h and at 5
days after hospital admission.
Methods
Study design
RELAX-AHF was a phase III randomized, double-blind, placebo-
controlled, parallel-group, international trial comparing the i.v. admin-
istration of serelaxin for up to 48 h, started within 16 h of presentation,
with placebo in patients hospitalized for AHF with dyspnoea, conges-
tion on chest radiography, increased natriuretic peptide levels, mild to
moderate renal insufficiency, and systolic blood pressure >125mmHg.
Patients were enrolled in the USA, Israel, Western Europe (France,
Germany, Italy, The Netherlands, and Spain), Poland, Hungary, Roma-
nia, and Argentina. The background, design, and main results have
been published elsewhere.14,15 This trial is registered at ClinicalTri-
als.gov (NCT00520806), complies with the Declaration of Helsinki,
and a locally appointed ethics committee or institutional review board
has approved the research protocol with written informed consent
obtained from each patient.
Procedures
In the RELAX-AHF phase III study, blood samples, weight, and diuretic
dose were collected in all patients at baseline and at 24 h (day 1);
48 h (day 2); on days 3 and 4, if in hospital; and on days 5, 14, and
60 for standard haematology and chemistry at a central laboratory
























































































.. including troponin T and NT-proBNP were collected at baseline and
days 2, 5, and 14, and were analysed centrally. The endpoints of interest
were (i) change in patient-reported dyspnoea as quantified by the
area under the curve (AUC) of the change from baseline in visual
analogue scale (VAS) scores (0–100mm scale) from baseline to day
5 (a primary endpoint of RELAX-AHF); (ii) cardiovascular death or
readmission to hospital for heart failure or renal failure through day 60
(a secondary endpoint of RELAX-AHF); and (iii) cardiovascular death
through day 180. As specified in the analysis plan for the main study,
the dyspnoea VAS score was imputed as the worst observed score
following a death or worsening heart failure event when calculating
the AUC of the change from baseline. All deaths and rehospitalizations
were adjudicated by the clinical events committee.
Definitions
Diuretic response was defined as change in weight (kg) from baseline
to day 5/[(total i.v. dose)/40mg]+ [(total oral dose)/80mg] furosemide
up to day 5. The last available weight was substituted for a missing
day 5 weight. Additional comparative analyses were performed on
diuretic response from baseline to 48 h. Loop diuretic doses consid-
ered equivalent to 40mg of furosemide were 2mg of bumetanide,
20mg of torasemide, and 50mg of ethacrynic acid. Worsening renal
function was defined as an increase in serum creatinine of ≥0.3mg/dL
to day 5 (or day 4, if day 5 was missing)).
Statistical analyses
Mean and standard deviation, or geometric mean and 95% confi-
dence interval, are presented for continuous variables, and absolute
and relative frequencies for categorical variables. Because its distribu-
tion was highly skewed, and associations with outcomes non-linear,
diuretic response was grouped by tertiles for analysis. Baseline char-
acteristics were compared among diuretic response tertiles using the
Jonckheere–Terpstra (J-T) trend test. Patients with missing values of
diuretic response were deleted from the analyses in which diuretic
response appears as an outcome variable. For analyses of clinical end-
points in which diuretic response appears as an explanatory factor,
missing values of diuretic response were imputed so as to include those
patients, thus preserving comparability with other such analyses. Sam-
ple sizes in the tables reflect these distinctions.
A multivariable cumulative logit model predicting diuretic response
was developed using backwards elimination in the full study population,
with P< 0.10 as the criterion for retention in the model. The treatment
group-specific median or mode was imputed for missing continuous
and categorical variables, respectively. A list of potential covariates was
reduced by choosing one representative in certain groups of related
covariates to represent the effect, e.g. alanine aminotransferase (ALT)
or aspartate aminotransferase (AST), or haemoglobin or haematocrit,
based on the lowest Akaike information criterion (AIC) in univariable
analyses. The linearity of the association between the log cumulative
odds and selected continuous candidate predictors was then assessed
using restricted cubic splines, and, if significant non-linearity was found
(at P< 0.10), we used the dichotomy or quadratic or cubic polynomial
which had the lowest AIC. The interaction of each effect with serelaxin
was then tested and, where significant at P< 0.10, the interaction was
added to the effects to consider in the backwards elimination.
The associations of diuretic response with clinical outcomes
(dyspnoea VAS AUC to day 5, cardiovascular death, or heart fail-
ure/renal failure rehospitalization through day 60, and cardiovascular
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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mortality through day 180) were adjusted for covariates found to
be associated with these outcomes in the placebo group only using
multivariable linear regression and Cox regression models. Wald test
𝜒2 statistics and P-values are reported. SAS release 9.3 (SAS Institute,
Cary, NC, USA) was used for all analyses.
Role of the funding source
The study was designed by the members of the executive committee,
which included two Corthera clinical scientists, and was part of a
phase II/III trial design. Data collection and analysis were performed
by contract research organizations. The study database was held both
by the Sponsor and by Columbia University (New York, USA). The
authors had access to tables and listings supplied by the sponsor
and Columbia but did not have independent access to the study
databases. The executive committee had full access to the final tables
and figures. The authors not employed by the sponsor had ultimate
editorial authority, with no interference by the sponsor in their final
interpretation.
Results
The main results of RELAX-AHF have been published
elsewhere.14,15 During the first 5 days of hospital admission,
the median weight change was −2.2 kg, median total i.v. dose of
furosemide was 80mg, and median total oral dose of furosemide
was 160mg. The majority of patients received furosemide (92.2%);
torsemide was administered to 9.0%, bumetanide to 1.3%, and
ethacrynic acid to 0.95%. (A given patient may have received more
than one type of loop diuretic.) Of the 1161 patients randomized,
7 died by day 5 and were excluded from the analyses. Fifty-seven
patients were missing data such that the diuretic response could
not be derived, and 70 patients were missing data on worsening
renal failure. Daily weights and loop diuretic doses are provided in
the Supplementary material online Figures S1 and S2.
Predictors of diuretic response
The median diuretic response was −0.42 kg/40mg [interquartile
range (IQR) –1.00, −0.14 kg/40mg]. There were marked differ-
ences across the tertiles of diuretic response, as presented in
Table 1. Poor responders (with higher diuretic response values)
were more frequently found in Western-like countries (Western
Europe, North America, Poland, and Israel). Also, poor diuretic
responders were more likely to have ischaemic heart failure, a
higher NYHA class 1month prior to enrolment, lower systolic and
diastolic blood pressures, fewer signs of congestion, and a poorer
baseline renal function, and were more often on oral loop diuret-
ics 1 month prior to enrolment. Other characteristics related to
diuretic response are given in Table 1.
Independent predictors of diuretic response are presented in
Table 2. The most significant predictors of a poor diuretic response
were Western-like region (Western Europe, North America,
Israel, and Poland), lower diastolic blood pressure, the absence
of oedema, higher blood urea nitrogen (BUN), and lower levels



















































































.. diuretic response at 48 h are presented in Supplementary mate-
rial online Table S1, and were largely similar to the predictors of
diuretic response at day 5.
Effects of serelaxin on diuretic response
The median (25th, 75th percentile) total i.v. loop diuretic dose
before day 5 was 100 (20, 240) mg in the placebo group and 80
(0, 200) mg in the serelaxin group; median (25th, 75th percentile)
total dose of oral loop diuretic dose through day 5 was 137.5 (40,
270) and 160 (80, 240), respectively. As defined for this analysis,
median change in body weight at day 5 was −2.4 kg (IQR −4.8,
−1.0) in the placebo group vs. –2.0 (IQR −4.0, −0.8) kg in the
serelaxin group (P= 0.133). On univariable analysis, randomization
to serelaxin was not associated with diuretic response: median of
−0.42 (IQR −0.94, −0.15) kg/40mg in the placebo group vs. –0.42
(IQR −1.09, −0.13) kg/40mg in the serelaxin group (P= 0.644).
Although a statistically significant serelaxin by EF interaction effect
was included in the multivariable model, the slight worsening of
diuretic response in the serelaxin group, and slight improvement in
diuretic response in the placebo group, with increasing LVEF were
small and possibly due to chance. In addition, we performed similar
analyses on the effects of serelaxin on diuretic response at 48 h. As
can be seen from Table S2 of the Supplementary material online,
there was no significant difference in diuretic response at day 2
between treatment groups.
Worsening renal function and diuretic
response
Worsening renal function, defined as an increase in serum creati-
nine of≥0.3mg/dL to day 5 (or day 4, if day 5 was missing), occurred
in 280 of the 1084 patients (26%) with available data. Table 3 shows
that patients with both worsening renal function and poor diuretic
response (less than the median response) had the worst 60- and
180-day outcomes, but the risks were not more or less than the
combined individual effects would predict (interaction P-values 0.72
and 0.53 for 60- and 180-day outcomes, respectively).
Diuretic response and clinical outcomes
In univariable analyses, diuretic response was significantly associ-
ated with the dyspnoea VAS AUC to day 5 (P= 0.0015; Figure 1)
and cardiovascular death or heart failure/renal failure rehospital-
ization through day 60 (P< 0.0001; Figure 2) but not with cardio-
vascular mortality through day 180 (P= 0.13; Table 4). After mul-
tivariable adjustment for baseline characteristics, worse diuretic
response remained independently associated with a poorer dys-
pnoea relief to day 5 (P= 0.0002; Table 4) and with 60-day car-
diovascular death or heart failure/renal failure rehospitalization
(P< 0.0001). These associations were independent of worsening
renal function (Figure 3). Further adjustment for changes to day 2 in
BUN, creatinine, sodium, total protein, and log NT-proBNP did not
change these associations significantly. However, diuretic response
was not independently associated with mortality through day 180
(P= 0.507).
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics according to tertiles of diuretic response (defined as change in weight/[(total i.v.
dose)/40mg]+ [(total oral dose)/80mg)] furosemide up to day 5)
≤ −0.75 kg/40mg
(n= 365)
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Demographics and heart failure characteristics
Age (years) 71.5 (11.5) 72.7 (10.4) 72.2 (11.6) 0.4997
Male 220 (60.3) 228 (62.3) 237 (64.8) 0.2112
White/Caucasian 353 (96.7) 348 (95.1) 343 (93.7) 0.0590
Geographic region <0.0001
Eastern EU 227 (62.2) 162 (44.3) 142 (38.8)
Western EU 58 (15.9) 57 (15.6) 80 (21.9)
South America 27 (7.4) 28 (7.7) 14 (3.8)
North America 25 (6.8) 35 (9.6) 41 (11.2)
Israel 28 (7.7) 84 (23.0) 89 (24.3)
LVEF 39.2 (13.9) 38.6 (14.8) 37.9 (14.9) 0.0906
Ischaemic heart disease 155 (42.5) 215 (58.7) 207 (56.6) 0.0001
Time from presentation to randomization (h) 7.9 (4.5) 7.7 (4.6) 8.0 (4.8) 0.9190
CHF 1 month prior 242 (66.3) 293 (80.1) 292 (79.8) <0.0001
NYHA class (I/II/III/IV) 30 days before admission <0.0001
I 126 (34.6) 82 (22.6) 83 (23.1)
II 108 (29.7) 112 (30.9) 73 (20.3)
III 105 (28.8) 117 (32.2) 150 (41.7)
IV 25 (6.9) 52 (14.3) 54 (15.0)
Clinical signs
Body mass index, kg/m2 29.8 (6.0) 29.4 (5.6) 28.9 (5.4) 0.1033
Systolic blood pressure, mmHg 145.0 (16.5) 140.4 (15.3) 140.7 (16.9) <0.0001
Diastolic blood pressure, mmHg 81.9 (14.4) 78.2 (13.7) 76.4 (13.6) <0.0001
Heart rate, b.p.m. 81.7 (15.4) 78.5 (14.6) 78.1 (14.6) 0.0008
Respiratory rate, breaths/min 21.8 (4.4) 21.8 (4.6) 22.1 (5.0) 0.8207
HF hospitalization past year 96 (26.3) 131 (35.8) 154 (42.1) <0.0001
Congestion at baseline
Oedema 305 (83.6) 306 (83.8) 265 (72.4) <0.0001
Orthopnoea 350 (96.2) 352 (96.2) 350 (95.6) 0.3781
JVP 283 (80.4) 275 (76.8) 252 (70.2) 0.0031
Dyspnoea on exertion 361 (99.7) 359 (99.7) 359 (99.4) 0.0907
Dyspnoea by VAS 44.6 (20.1) 43.9 (20.8) 43.5 (19.6) 0.1714
Rales 138 (37.8) 141 (38.5) 156 (42.6) 0.4716
Co-morbidities
Hypertension 312 (85.5) 323 (88.3) 312 (85.2) 0.9256
Hyperlipidaemia 158 (43.3) 216 (59.0) 209 (57.1) 0.0002
Diabetes mellitus 151 (41.4) 189 (51.6) 183 (50.0) 0.0197
Cigarette smoking 45 (12.3) 45 (12.3) 46 (12.6) 0.9217
Stroke or other cerebrovascular event 44 (12.1) 49 (13.4) 58 (15.8) 0.1369
Peripheral vascular disease 46 (12.6) 53 (14.5) 43 (11.7) 0.7300
Asthma, bronchitis, or COPD 46 (12.6) 54 (14.8) 72 (19.7) 0.0086
AF at screening 176 (48.2) 147 (40.2) 133 (36.5) 0.0014
History of AF or atrial flutter 207 (56.7) 187 (51.1) 183 (50.0) 0.0694
History of CRT or ICD procedures 63 (17.3) 106 (29.0) 113 (30.9) <0.0001
Myocardial infarction 100 (27.4) 136 (37.2) 147 (40.2) 0.0003
Depression 16 (4.4) 16 (4.4) 24 (6.6) 0.1817
Devices
Pacemaker 33 (9.0) 41 (11.2) 44 (12.0) 0.1937
ICD 28 (7.7) 56 (15.3) 63 (17.2) 0.0002
Biventricular pacing 17 (4.7) 43 (11.7) 46 (12.6) 0.0003
Medication (day 0, except nitrates and loop diuretics)
ACE inhibitor 202 (55.3) 214 (58.5) 187 (51.1) 0.2476
ACE inhitor or ARB 245 (67.1) 275 (75.1) 234 (63.9) 0.3507
ARB 56 (15.3) 66 (18.0) 58 (15.8) 0.8549
Beta-blocker 227 (62.2) 267 (73.0) 263 (71.9) 0.0048
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Aldosterone antagonist 130 (35.6) 116 (31.7) 104 (28.4) 0.0368
I.v. loop diuretics 365 (100.0) 366 (100.0) 366 (100.0) NA
Digoxin 85 (23.3) 53 (14.5) 74 (20.2) 0.2952
Nitrates at randomization 35 (9.6) 16 (4.4) 26 (7.1) 0.1897
Oral loop diuretics 30 days prior to randomization 25 (31.5) 47 (52.1) 67 (93.0) <0.0001
Baseline labs
Sodium, mmol/L 141.1 (3.6) 141.0 (3.3) 140.4 (3.8) 0.0137
Phosphate, mmol/L 1.18 (0.45) 1.19 (0.24) 1.19 (0.24) 0.4206
Calcium, mmol/L 2.27 (0.153) 2.26 (0.159) 2.27 (0.150) 0.6419
Haemoglobin, g/dL 13.01 (1.79) 12.62 (1.92) 12.71 (1.90) 0.0244
White blood cell count, ×109/L 8.168 (2.697) 7.907 (2.654) 8.222 (2.927) 0.8668
Lymphocytes, % 18.39 (7.98) 18.71 (8.19) 17.41 (7.08) 0.2053
Potassium, mmol/L 4.32 (0.66) 4.26 (0.62) 4.25 (0.63) 0.2173
Creatinine, μmol/L 111.6 (32.2) 116.6 (32.0) 122.4 (33.9) <0.0001
Uric acid, μmol/L 461.8 (135.9) 475.5 (125.6) 495.4 (144.8) 0.0018
Troponin T, μg/L 0.035 (0.032, 0.038) 0.034 (0.032, 0.038) 0.036 (0.033, 0.039) 0.2982
BUN, mmol/L 8.96 (3.36) 9.78 (3.73) 10.69 (4.54) <0.0001
Cystatin C, mg/L 1.38(1.34, 1.42) 1.47 (1.42, 1.51) 1.54 (1.49, 1.58) <0.0001
Alanine aminotransferase, U/L 25.3 (23.7, 27.1) 21.6 (20.3, 22.9) 23.1 (21.7, 24.6) 0.0349
NT-proBNP, ng/L 5218 (4760, 5720) 4861 (4417, 5349) 5107 (4659, 5599) 0.2983
NT-proBNP, ng/L in patients with AF present at screening 5566 (4979, 6223) 5203 (4546, 5955) 5086 (4455, 5806) 0.1929
NT-proBNP ng/L in patients with AF not present at screening 4909 (4247, 5675) 4645 (4070, 5302) 5133 (4531, 5814) 0.9200
eGFR, mL/min/1.73m2 55.36 (12.45) 52.91 (13.32) 51.52 (12.66) <0.0001
Total cholesterol, mmol/L 4.20 (1.17) 3.98 (1.17) 4.06 (1.13) 0.0624
Glucose, mmol/L 7.34 (3.51) 7.91 (3.57) 8.04 (3.71) 0.0003
Albumin, g/L 39.99 (4.31) 40.04 (4.72) 40.58 (3.87) 0.1819
BUN, blood urea nitrogen; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; JVP, jugular
venous pressure; NA, not applicable; VAS, visual analogue scale.
aP-values are for the Jonckheere–Terpstra trend test, except for geographic region for which the Kruskal–Wallis test P-value is presented.
Discussion
The main finding of the present study is that a poor diuretic
response is a strong and independent predictor of poorer dyspnoea
relief and an increased risk of cardiovascular death or heart
failure/renal failure hospital readmission through day 60 in patients
admitted for AHF. Serelaxin treatment was associated with less
diuretic use, but a neutral effect on diuretic response.
Recently, Valente et al. and Testani et al. presented a simple met-
ric for diuretic responsiveness in patients admitted for AHF.12,13
The metric of weight loss/unit loop diuretic had additive prognos-
tic value on top of weight loss or dose of loop diuretic alone. In
both studies, diuretic response was related to clinical outcome.
The present study confirms these findings, but adds information
on the predictors of diuretic response and the absence of an effect
of serelaxin on diuretic response. We additionally showed that pre-
dictors of diuretic response and the effects of serelaxin were similar
between 48 h and day 5.
Association between poor diuretic
response and poor clinical outcome
The relationship between diuretic response and early outcomes



































.. might have adversely influenced clinical outcome. However, the
DOSE-AHF (Diuretic Optimization Strategies Evaluation in Acute
Heart Failure) trial, which compared a higher vs. a lower dose of
diuretics in AHF patients, found that the higher dose was associ-
ated with greater diuresis and transient worsening of renal func-
tion, but did not significantly affect patients’ global assessment of
symptoms.16 Secondly, patients with a poorer diuretic response
might simply reflect sicker patients, and are therefore likely to
have a poorer outcome. However, levels of NT-proBNP at admis-
sion were remarkably similar, and the predictive value of diuretic
response remained remarkably consistent after adjusting for poten-
tial confounders. Thirdly, diuretic response might be a deleterious
condition by itself, causing a poor clinical outcome. It is conceiv-
able that a poor diuretic response results in less relief of dyspnoea,
as was shown in the present study. Metra et al. previously demon-
strated that less dyspnoea relief during hospitalization is indepen-
dently related to a poorer clinical outcome.17 Also, the associa-
tion between diuretic response and clinical outcome seems to be
mainly driven by early discharge rehospitalization, and less by mor-
tality. These findings support that a poor diuretic response might
cause less relief of dyspnoea and congestion, potentially leading to
a greater risk of rehospitalization.
This is of importance for two reasons. First, we are better
able to predict those patients at higher risk for rehospitalization,
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Table 2 Multivariable predictors of poor diuretic responsea
Covariate OR Lower 95% CI Upper 95% CI Wald 𝝌2 P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Region, Western-like 2.514 1.889 3.347 39.90 <0.0001
Weight (kg) 0.993 0.986 1.000 3.46 0.0630
Diastolic blood pressure (mmHg) 0.988 0.979 0.997 7.30 0.0069
Body temperature (∘C) 0.654 0.471 0.910 6.35 0.0117
Respiratory rate (breaths/min)b 6.88 0.0321
Median (21) vs. 25th percentile (19) 0.941 0.878 1.008
75th percentile (24) vs. median (21) 0.976 0.902 1.057
HF hospitalization past year 1.364 1.056 1.763 5.63 0.0176
NYHA class 30 days prior 6.80 0.0779
NYHA II vs. I 0.768 0.551 1.069
NYHA III vs. I 1.135 0.807 1.594
NYHA IV vs. I 1.107 0.711 1.722
Oedema 23.99 <0.0001
Oedema, 1 vs. 0 0.689 0.489 0.970
Oedema, 2 vs. 0 0.531 0.374 0.753
Oedema, 3 vs. 0 0.385 0.258 0.575
Dyspnoea VAS (mm)c 6.72 0.0814
Median (45) vs. 25th percentile (30) 0.867 0.751 1.001
75th percentile (57) vs. median (45) 0.852 0.747 0.971
Percutaneous intervention 1.405 1.069 1.848 5.93 0.0149
Peripheral vascular disease 0.693 0.489 0.983 4.23 0.0397
Hyperthyroid 2.191 1.077 4.458 4.69 0.0304
Atrial fibrillation/flutter at screening 0.733 0.578 0.929 6.59 0.0103
BUN (mmol/L) 1.089 1.052 1.127 23.37 <.0001
Uric acid (μmol/L) 1.001 1.000 1.002 3.75 0.0529
Aspartate aminotransferase, log(U/L) 0.686 0.527 0.893 7.86 0.0050
Sodium (mmol/L) 0.960 0.927 0.993 5.53 0.0187
Potassium (mmol/L) 0.706 0.577 0.864 11.36 0.0007
Total protein (g/L) 1.022 1.003 1.042 4.92 0.0265
NT-proBNP, > median vs. ≤ median 0.735 0.571 0.945 5.76 0.0164
LVEF by serelaxin interaction 4.26 0.0390
LVEF (%), placebo 0.991 0.979 1.003 0.1472
LVEF (%), serelaxin 1.008 0.997 1.020 0.1634
Odds ratios (are for a one unit increase in the covariate unless otherwise specified.
BUN, blood urea nitrogen; CI, confidence interval; HF, heart failure; OR, odds ratio; VAS visual analogue scale.
aCumulative logit model of diuretic response tertile.
bNon-linear association modelled as a quadratic polynomial.
cNon-linear association modelled as a cubic polynomial.
which is a major problem in patients who are admitted for AHF.
Secondly, and more importantly, strategies that improve diuretic
response might lead to improved clinical outcome and fewer
rehospitalizations in patients with AHF. However, potential strate-
gies to improve diuretic response remain to be established. First,
addition of thiazides/chlorothalidon and/or azetazolamide might
improve diuretic response, although this should be proven by
prospective randomized controlled trials. Ultrafiltration might be
another option to improve diuretic response in diuretic-resistant
patients. In UNLOAD, in AHF patients with signs of volume
overload, ultrafiltration resulted in greater weight and fluid loss
than i.v. diuretics, but had no effect on mortality.18 These beneficial
effects could not be confirmed in a recent randomized trial, where
loop diuretics were superior to ultrafiltration for the preserva-






















. However, a good diuresis was observed in both arms, indicating
that these patients were not diuretic resistant, although the results
might be different in a population of patients selected based on a
poor diuretic response.
Mechanisms behind a poor diuretic
response
What are the potential mechanisms behind the diuretic response?
Obviously, patients with a poor diuretic response have a poorer
renal function. However, similar to the studies by Valente et al.
and Testani et al., renal dysfunction explains only a part of poor
diuretic response.12,13 There are a number of explanations for this.
First, Valente et al. demonstrated that diuretic-resistant patients
more often had heart failure of ischaemic origin and signs of
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Table 3 Clinical outcome according to worsening renal function and diuretic response


















. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dyspnoea improvement
by VAS AUC to day 5,
mean (SD)
2788.1 (2600.4) 2356.2 (2735.0) 2889.2 (3187.7) 2348.5 (3309.3) 0.9988 0.2024
Cardiovascular death or
rehospitalization for
HF or renal failure
through day 60, n
(Kaplan–Meier %)
29 (7.49) 66 (17.33) 13 (9.56) 26 (19.05) 0.7362 0.7206
Cardiovascular mortality
through day 180, n
(Kaplan–Meier %)
23 (5.97) 26 (6.86) 10 (7.36) 16 (11.79) 0.7238 0.5262
A good diuretic response is defined as a response greater than the median.
AUC, area under the curve; HF, heart failure; SD, standard deviation; VAS, visual analogue scale; WRF, worsening renal function.
aEach outcome is adjusted for the covariates given in the footnotes to Table 4.
Figure 1 Changes in visual analogue scale through to day 5 in tertiles of diuretic response (DR).
atherosclerosis.12 A similar picture emerges in the present study.
Patients with a poor diuretic response more often had ischaemic
heart failure, a previous myocardial infarction, dyslipidaemia, and
diabetes. A poorer diuretic response in atherosclerotic patients
might be caused by atherosclerotic kidneys that are less likely to
respond to diuretics. Alternatively, the presence of renal artery
stenosis may be prevalent in patients with ischaemic heart failure20
and might also explain a poorer diuretic response, although we













. a poor diuretic response in the present study also had fewer
signs of congestion. These patients might have AHF due to fluid
redistribution, rather than fluid accumulation, and therefore they
will not respond to diuretics. Loop diuretics might not be the
best treatment option in these patients as they are not volume
overloaded, and they might even be deleterious, causing relative
dehydration and worsening renal function. So, it is reasonable
to suggest that diuretic response is better in more congested
patients with more peripheral oedema, but it should be noted
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Figure 2 Kaplan–Meier survival curves presenting death or HF/RF readmission through day 60 according to tertiles of diuretic response.
P< 0.0001 for log-rank test comparing diuretic response tertiles.
Table 4 Associations of diuretic response with selected outcomes
Unadjusted Adjusted
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Outcome Contrast Measure of association
(95% CI)
P-value Measure of association
(95% CI)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dyspnoea VAS AUC to day 5a 0.0002 0.0001
T2 vs. T1 −355.944 (−751.753, 39.866) −319.370 (−645.481, 6.740)
T3 vs. T1 −855.674 (−1265.072, −446.276) −749.944 (−1096.009, −403.879)




T2 vs. T1 1.122 (0.702, 1.794) 0.919 (0.566, 1.494) .
T3 vs. T1 2.735 (1.806, 4.142) 1.855 (1.195, 2.879) .
CV death through day 180c 0.1323 0.5069
T2 vs. T1 0.865 (0.502, 1.490) 0.948 (0.533, 1.689) .
T3 vs. T1 1.417 (0.856, 2.347) 1.273 (0.722, 2.244) .
T1= first tertile (≤ −0.75 kg/40mg), T2= second tertile (>− 0.75 to≤−0.22 kg/40mg), T3= third tertile (> −0.22 kg/40mg).
AUC, area under the curve; CI, confidence interval; CV, cardiovascular; HF, heart failure; RF, renal failure; VAS, visual analogue scale.
aMeasure of association is mean change from linear regression model. Adjusted for age, weight, hypertension, mitral regurgitation, history of atrial fibrillation or flutter,
USA-like region, dyspnoea on exertion, body temperature, troponin T, baseline dyspnoea VAS score, uric acid, alkaline phosphatase, and sodium.
bMeasure of association is hazard ratio from Cox regression model. Adjusted for white race; NYHA class 30 days prior; systolic blood pressure; respiratory rate; number of
HF hospitalizations in past year; orthopnoea; asthma, bronchitis, or COPD; hyperthyroid; lymphocyte %; blood urea nitrogen; phosphate; sodium; and total protein.
cMeasure of association is hazard ratio fromCox regression model. Adjusted for USA-like region, systolic blood pressure, orthopnoea, angina, hyperthyroid, mitral regurgitation,
atrial fibrillation or flutter at screening, white blood cell count, lymphocyte %, blood urea nitrogen, sodium, potassium, calcium, total protein, troponin T, and NT-proBNP.
that the poorer prognosis in diuretic-unresponsive patients was
independent of the baseline level of congestion. Finally, we showed
that worsening renal function (using the most commonly used
definition of an increase in serum creatinine of≥0.3mg/dL to day 5)







. was an important predictor of diuretic response. This supports the
concept that diuretic response is not primarily driven by glomerular
filtration, but more by tubular function.21 Therefore, markers
of tubular function and/or damage might better predict diuretic
response than markers of glomerular function. Unfortunately,
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Figure 3 Kaplan–Meier survival curves presenting death or HF/RF readmission through day 60 in 1) patients with WRF and a poor diuretic
response (<median); 2) patients with WRF and a good diuretic response (>median); 3) patients without WRF and a poor diuretic response
(<median); 4) patients withoutWRF and a good diuretic response (>median). P= 0.7362 forWald chi-square test of diuretic response- by-WRF
interaction.
we did not collect urine in RELAX-AHF, and do not have data on
plasma markers of tubular damage.
Effects of serelaxin on diuretic response
Despite a significant reduction in dyspnoea and lower 180-day
mortality, serelaxin did not influence diuretic response in these
patients. However, patients treated with serelaxin required lower
doses of diuretics and had slightly less weight loss, which may
have balanced the effects on diuretic response. Also, serelaxin
was related to less deterioration of renal function. There-
fore, the beneficial effects of serelaxin cannot be explained by
improved diuretic response, and a potential explanation might be
related to prevention of organ damage, as has been postulated
previously.22
Limitations
The present study has obvious limitations that are related to the
retrospective nature of the findings. Therefore, the suggestion that
a poor diuretic response might cause a poor clinical outcome
cannot be proven. Also, this study was not designed to examine
the consequences of diuretic response, and therefore there are
important data lacking, such as urinary collections and markers of
tubular function/damage. Furthermore, it is well known that weight
recordings are notoriously unreliable. In addition, diuretic doses











































. these limitation, the simple metric of weight loss divided by diuretic
dose is clearly related to in-hospital and post-discharge outcome
in patients admitted for AHF.
Conclusion and clinical
implications
In a large cohort of patients admitted for AHF, a poor diuretic
response was related to less improvement in dyspnoea through
the first 5 days, and an increased risk of cardiovascular death
or heart failure/renal failure rehospitalization through 60 days.
Future studies should aim at predicting diuretic response in patients
admitted with acute decompensated heart failure and should lead
to prospective intervention studies, aiming to improve diuretic
response, potentially leading to further improvement in dyspnoea,
less early mortality, and fewer heart failure rehospitalizations.
Supplementary Information
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Table S1. Multivariable predictors of poor diuretic response
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